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INTRODUCTION 39
Influenza viruses continuously infect humans, in large part due to their ability to rapidly 40 escape human immunity (Yewdell, 2011) . Most neutralizing antibodies against influenza viruses 41 target the globular head domains of hemagglutinin (HA) proteins and inhibit viral replication by 42 blocking viral attachment. These types of antibodies often become ineffective after viruses 43 acquire substitutions in epitopes within the HA globular head through a process called antigenic 44 drift. As a result, seasonal influenza virus infections or vaccinations typically provide limited 45 protection against antigenically drifted strains. New 'universal' vaccine antigens are currently 46 being developed to elicit broadly-reactive antibodies against conserved epitopes in the HA 47 neutralized virus in vitro while the remaining 5 were non-neutralizing ( Figure 1B) . Several HAI-91 mAbs inhibited binding of the HA stalk-reactive F49 mAb in competition assays (Supplemental 92 Figure 1 ), suggesting that these mAbs targeted epitopes in lower regions of HA. These data are 93 consistent with previous studies (Angeletti and Yewdell, 2018) that suggest that the majority of 94 antibodies elicited by seasonal influenza vaccines target neutralizing epitopes on the HA 95 globular head. 96 97
Most vaccine-elicited human H3 mAbs target HA antigenic site B 98
To map the footprints of each mAb, we measured binding to a panel of 99 to express A/Perth/16/2009 HAs with the N145D, F159G, F159S, K160T, or I192E substitutions. 169 As expected, site B substitutions dramatically reduced neutralization of the narrowly-reactive 170 024-10128-3C04 mAb ( Figure 4C ). Substitutions at residues 145, 159, and 160 also reduced 171 neutralization of the 019-10117-3C06 mAb, but importantly, all mutant viruses tested were still 172 moderately neutralized by this mAb ( Figure 4D ). As a control, we also tested binding of the 028-173 10134-4F03 mAb, which binds lower on the HA head, against the 024-10128-3C04 and 019-174 10117-3C06 escape mutants. As expected, this mAb neutralized these mutants equivalently 175 ( Figure 4E ). These data indicate that viruses can acquire HA substitutions that decrease 176 neutralization of the broadly reactive 019-10117-3C06 mAb but that these substitutions do not 177 completely escape from this antibody. 178
We hypothesized that the 019-10117-3C06 mAb is able to partially recognize viruses 179 with HA antigenic site B substitutions by engaging conserved residues in the HA RBS. To test 180 this hypothesis, we measured antibody binding to HAs that possessed a K160T HA substitution 181 that introduces a glycosylation site in HA antigenic site B (Zost et al., 2017) with and without an 182 additional Y98F substitution. HA residue 98 is located at the base of the RBS and interacts 183 directly with sialic acid (Figure 2 and (Whittle et al., 2014) ). Previous studies have shown that 184 the Y98F substitution prevents HA binding to sialic acid without affecting the overall structure of 185 HA (Bradley et al., 2011; Martín et al., 1998; Whittle et al., 2014) . Consistent with our previous 186 analyses (Figure 2) , the 019-10117-3C06 mAb had moderate reductions in binding to HAs 187 possessing either the K160T or the Y98F HA substitutions (Figure. 5A) . Importantly, the 019-188 10117-3C06 mAb had dramatically reduced binding to HAs possessing both of these mutations 189 ( Figure 5A ). As a control, we also tested binding of the narrow 024-10128-3C04 mAb to HAs 190 possessing the K160T substitution with or without the Y98F substitution. Unlike the broadly 191 reactive 019-10117-3C06 mAb, the narrow 024-10128-3C04 mAb failed to efficiently bind to 9 dependent on interactions with conserved residues in the RBS. 195 196 
Some individuals possess high levels of broadly-reactive HA RBS-targeting antibodies 197
We completed ELISAs to determine if HA RBS-targeting antibodies were present at high 198 frequencies in the sera of donors pre-and post-vaccination. We tested sera from 28 individuals 199 vaccinated during the 2010-2011 season, including 10 of the 13 donors that were used to 200 generate mAbs. We tested sera antibody binding to ELISAs coated with A/Victoria/210/2009 201 HA, A/Victoria/210/2009 HA with a Y98F RBS substitution, A/Hong Kong/4801/2014 HA (a 202 drifted strain with HA antigenic site B mutations), and A/Hong Kong/4801/2014 HA with a Y98F 203 RBS substitution. Most sera samples did not have reduced antibody reactivity to HAs that were 204 engineered to express the Y98F HA substitution, suggesting that the majority of antibodies in 205 the serum of these vaccinated individuals were not directed against conserved residues of the 206 RBS. However, serum antibodies from one donor (019-10117) had dramatically reduced binding 207
to HAs with the Y98F substitution ( Figure 6 ). Notably, the broadly reactive 019-10117-3C06 HA 208 RBS-targeting mAb was derived from this same donor. This donor possessed Y98F-sensitive 209 antibodies both prior to and after vaccination ( Figure 6 ). Just like the 019-10117-3C06 mAb, 210 polyclonal serum antibodies from this donor partially bound to the drifted A/Hong 211 Kong/4801/2014 HA and binding of these antibodies was reduced by the Y98F HA substitution. 212
213

HA RBS-targeting antibodies are likely important in years with seasonal influenza 214 vaccine mismatches 215
It is possible that HA RBS-directed antibodies are an important part of polyclonal 216 neutralizing antibody responses during influenza seasons in which there are large antigenic 217 mismatches between vaccine strains and circulating strains. It has been historically difficult to 218 quantify levels of neutralizing HA RBS-directed antibodies in polyclonal sera. The main problem 219 is that neutralization assays cannot be completed with HAs that have RBS substitutions since 220 these substitutions often abrogate HA-sialic acid binding. To circumvent this problem, we 221 developed an absorption-based approach to fractionate human serum samples. For these 222 assays, we incubated serum antibodies with 293F cells expressing HAs with or without the 223 Y98F substitution and then we completed in vitro neutralization assays with HA-absorbed serum 224 fractions. In these assays, antibodies that are sensitive to the Y98F HA substitution are not 225 absorbed by 293F cells that express the Y98F HA. 226
As a proof of principle, we first tested the broadly-reactive 019-10117-3C06 HA RBS-227 targeting mAb in this assay. We also included the broadly-reactive 041-10047-1C04 mAb that 228 does not make contact with the HA RBS. For these experiments we tested binding and 229 neutralization of the antigenically advanced A/Hong Kong/4801/2014 viral strain. Absorptions 230 with 293F cells expressing the wild-type A/Hong Kong/4801/2014 HA completely removed both 231 antibodies ( Figure 7A ). Conversely, absorptions with 293F cells expressing A/Hong 232 Kong/4801/2014 HA with the Y98F substitution removed the control 041-10047-1C04 mAb but 233 did not remove the HA RBS-targeting 019-10117-3C06 mAb ( Figure 7A ). 234
We next characterized serum antibodies in 21 individuals that received the 2015-2016 235 seasonal vaccine. We studied antibody responses elicited against the 2015-2016 vaccine 236 because the H3N2 component of this vaccine was severely mismatched compared to A/Hong 237 Kong/2014-like H3N2 viruses that circulated that season ( Figure 7B ). We first completed 238 standard neutralization assays using the A/Switzerland/9715293/2013 vaccine strain and the 239 antigenically distinct A/Hong Kong/4801/2014 virus. As expected, vaccine-elicited antibodies did 240 not neutralize the mismatched A/Hong Kong/4801/2014 virus as efficiently as the 241 A/Switzerland/9715293/2013 vaccine strain ( Figure 7C ). However, the 242 A/Switzerland/9715293/2013 vaccine strain did boost serum antibody responses against 243 A/Hong Kong/4801/2014 in some individuals. In order to determine if these cross-reactive 244 antibodies were targeting conserved residues of the HA RBS, we completed absorption 245 fractionation assays using serum from the same 21 vaccinated donors. For these experiments, 246
we quantified the fraction of A/Hong Kong/4801/2014-reactive antibodies that were sensitive to 247 the HA Y98F substitution. We detected Y98F HA-sensitive A/Hong Kong/4801/2014-reactive 248 antibodies in 4 of 21 vaccinated donors ( Figure 7D -G). We found that absorption with A/Hong 249 Kong/4801/2014 WT HA depleted serum neutralizing antibodies, while absorption with A/Hong 250 Kong/4801/2014HA-Y98F left an absorption-resistant fraction of neutralizing antibodies. 251
Interestingly, some of these individuals had detectable RBS-targeting antibodies present prior to 252 vaccination ( Figure 7D ,F,G). ELISA quantification confirmed that the antibodies left following 253 A/Hong Kong/4801/2014HA-Y98F absorption bound to the A/Hong Kong/4801/2014 WT but not 254 to the A/Hong Kong/4801/2014HA-Y98F HA, which indicates that this absorption-resistant 255 fraction contained RBS-targeting antibodies (Supplemental Figure 2) . These data suggest that 256 cross-reactive HA RBS antibodies can be elicited by antigenically mismatched vaccines in some 257 individuals, although this is not common with current egg-based vaccine formulations. 258
259
DISCUSSION 260
A greater understanding of the specificity of anti-influenza virus antibody responses in 261 humans is useful for rationally designing new universal influenza vaccine antigens. We began 262 this study by antigenically charactering 33 H3 mAbs isolated from humans receiving a seasonal 263 influenza vaccine. We found that the majority of these mAbs targeted epitopes in variable 264 regions of the HA head. Some of these mAbs targeted conserved residues in the HA RBS but 265 were not broadly reactive since they were also highly sensitive to HA substitutions in adjacent 266 variable antigenic sites. However, we identified one HA RBS-targeting mAb that had exceptional 267 breadth. This mAb (019-10117-3C06) was also moderately sensitive to HA substitutions in 268 adjacent variable antigenic sites but was able to partially bind to antigenically drifted HAs. 269
Most HA RBS-targeting antibodies are not broadly reactive because their large binding 270 footprints require contacts outside of the narrow RBS. However, several broadly reactive HA 271 al., 2014; Lee et al., 2012; McCarthy et al., 2018; Schmidt et al., 2015b; Tsibane et al., 2012; 273 Whittle et al., 2011; Winarski et al., 2015; Xu et al., 2013) . A common feature of these broadly 274 reactive HA RBS-targeting antibodies is that they all have relatively long HCDR3s, which allow 275 them to minimize contacts on the rim of the RBS and maximize contacts with conserved RBS 276 residues. Our study highlights that HA RBS-targeting antibodies can be broadly reactive even if 277 they are moderately sensitive to substitutions in conventional antigenic sites near the RBS. The 278 019-10117-3C06 mAb from our study is clearly affected by substitutions in HA antigenic site B 279 ( Figure 2 ), but this antibody maintains binding to diverse H3 HAs ( Figure 3 ) likely through 280 multiple contacts with conserved residues in the RBS, which is facilitated by the antibody's 19 281 amino acid HCDR3. 282
Our studies indicate that current vaccines do not efficiently elicit broadly reactive HA 283 RBS-targeting antibodies in most individuals. We examined a cohort that received an 284 antigenically mismatched vaccine, and although some of the donors mounted a cross-reactive 285 antibody response, most of these cross-reactive antibodies were not binding to conserved 286 residues in the HA RBS. Most conventional vaccine antigens are prepared in fertilized chicken 287 eggs (Grohskopf et al., 2018) and contemporary egg-adapted H3N2 vaccine strains possess 288 substitutions in or near the RBS which allow more efficient viral growth in chicken eggs (Wu et 289 al., 2017; Zost et al., 2017) . We speculate that vaccines that do not have adaptive mutations in 290 the HA RBS might be better at eliciting antibodies targeting epitopes in the HA RBS of 291 circulating viral strains. Future studies should determine if vaccine antigens that are not 292 prepared in eggs are better able to elicit broadly reactive HA RBS-targeting antibodies. 293
The challenge, of course, is designing new vaccine antigens that are able to 294 preferentially elicit antibodies like 019-10117-3C06. Recent work has sought to selectively elicit 295 broadly-reactive HA head antibody responses through the use of "mosaic" nanoparticles that 296 display antigenically diverse HA RBS domains on the same nanoparticle (Kanekiyo et al., 2019) . 297
This vaccination strategy might selectively activate naïve B cells targeting the HA RBS and 298 might also selectively recall broadly-reactive memory B cells in secondary responses. One key 299 challenge moving forward will to be determine if unique prior exposure histories facilitate the 300 development of broadly reactive HA RBS-targeting antibodies. In our study, we identified some 301 donors with very high levels of these antibodies in polyclonal sera. In the case of donor 019-302 10117, these antibodies were already at high levels in polyclonal sera prior to vaccination. Is 303 there something genetically unique about donor 019-10117 or does that donor have a unique 304 exposure history that gave rise to a B cell response highly focused on conserved residues within 305 the HA RBS? While some studies have generated unmutated common ancestors and inferred 306 the immunogenic stimuli for broadly-reactive antibody lineages targeting the HA RBS ( volume of 50 μL PBS were added to each well. Turkey erythrocytes (12.5 μL of a 2.5% [vol/vol] 420 solution) were added and the sera, virus, and erythrocytes were gently mixed. After 1 hr at room 421 temperature, plates were scanned and titers were determined as the lowest concentration of 422 monoclonal antibody that fully inhibited agglutination. HAI assays were performed in duplicate 423 on separate days. 424 mAbs were serially diluted two-fold in round-bottom 96-well plates in 50μL serum-free Minimal 427 Essential Medium (MEM). 50 μL of MEM containing 100 TCID50 of virus was added to serially 428 diluted mAbs and the mAb-virus mixtures were incubated for 30 min at room temperature. 429
Following incubation, the mAb-virus mixtures were added to confluent monolayers of Darby canine kidney (MDCK) cells in 96-well plates and incubated for 1 hr at 37°C. After 431 incubation, the virus-antibody mixtures were removed and cells were washed with 180 μL MEM. 432
After washing, serial dilutions of each mAb were added back to cell monolayers in infection 433 media (MEM containing HEPES buffer, gentamycin, and 1 μg/mL TPCK-treated trypsin). The 434 cells were incubated for 3 days and neutralization titers were determined as the lowest 435 concentration of mAb that prevented cell death. MN assays were completed in duplicate on 436 separate days. 437
438
VLP Antigenic Mapping ELISAs 439
Point mutants of A/Victoria/210/2009 HA were generated in a codon-optimized HA gene by site 440 directed mutagenesis. Virus-like particles (VLPs) were generated by transfecting 293T cells with 441 each point mutant along with plasmids encoding HIV gag, the NA from A/Puerto Rico/8/1934, 442 and a human-airway trypsin-like protease (HAT). Supernatants from transfected 293T cells were 443 collected 3 days following transfection and were concentrated by centrifugation at 19,000 rpm 444 (65,096 x g) in an SW-28 rotor using a 20% sucrose cushion. VLP pellets were resuspended in 445 PBS and stored at 4°C. ELISA plates were coated with HA-normalized point-mutant VLPs 446 diluted in PBS or just PBS as a background control and stored overnight at 4°C. The following 447 day, plates were blocked with a 3% w/vol solution of bovine-serum albumin (BSA) in PBS for 2 448 hrs. After blocking, plates were washed five times with distilled water and two-fold serial 449 dilutions of each mAb were added to plates in a 1% w/vol solution of BSA in PBS. After 2 hrs of 450 incubation, plates were washed and a peroxidase-conjugated goat anti-human secondary washed and 50μL of TMB substrate was added to each well. The TMB reaction was quenched 453 by addition of 25 μL 250mM HCl and absorbance at 450nm was measured using a plate reader. 454
In order to generate antigenic maps, one-site specific binding curves were fit to the data in 455
GraphPad Prism software and the maximal binding (Bmax) was determined for each mAb. To 456 generate antigenic maps from the ELISA data, we first selected the lowest mAb concentration 457 that still gave at least 90% of the Bmax signal. At this dilution, background signal was subtracted 458 and signal for each point mutant was normalized to the A/Victoria/210/2009 WT HA VLP signal. 459
Antigenic mapping ELISAs were conducted for each mAb in duplicate on separate days, and 460
the resulting values were averaged and represented as a heatmap. 461 expression vectors and the transmembrane was removed and replaced with the FoldOn 465 trimerization domain from T4 fibritin, an AviTag site-specific biotinylation sequence, and a 466 hexahistidine tag, as previously described (Whittle et al., 2014) . Recombinant HAs were 467 produced by transfecting 293F suspension cells with plasmids encoding HA. After four days, the 468 supernatant was clarified by centrifugation and the HA proteins were purified by Ni-NTA affinity 469 chromatography. 470 471
Mutational Antigenic Profiling 472
We performed mutational antigenic profiling of mAbs 024-10128-3C04 and 019-10117-3C06 473 against A/Perth/16/2009 (H3N2) HA mutant virus libraries (Lee et al., 2018) using a previously 474 described protocol (Doud et al., 2017) . We selected two biological replicate libraries by 475 incubating 1e6 TCID50 mutant viruses with neutralizing concentrations of antibody at 37°C for 476 1.5 hours. For antibody 024-10128-3C04, we neutralized mutant viruses with 0.1, 0.25, 0.2, 477 0.65, or 1 ug/ml antibody, and for 019-10117-3C06 we neutralized with 0.1, 0.2, 0.25, 0.55, 0.7, or 1 ug/ml antibody. We also included a mock selection condition where virus library was and resuspended at the desired volume. In the case of absorption-neutralization assays, RDE-557 treated serum samples were diluted in 293F media at a dilution of 1:80 and split into three 558 fractions for the three absorption conditions. An equivalent volume of 293F media containing 559 approximately 8x10 6 transfected cells/absorption reaction were added to each diluted serum 560 sample and the samples were mixed by shaking for 1 hr at room temperature. After incubation, 561 the cells were pelleted by centrifugation and the supernatant was transferred and re-centrifuged 562 to clarify. Absorbed supernatant containing the sera was then serially diluted in 96-well round-563 bottom plates in serum-free MEM and FRNT assays were conducted as described. Absorption-564 neutralization experiments were completed in triplicate on separate days. In the case of 565 absorption-ELISA assays, serum samples were diluted in 293F media at an initial dilution of 566 1:50 and split into three fractions for the three absorption conditions. Transfected cells were 567 added and absorption of serum antibodies was carried out as described above. Following 568 absorption, absorbed serum samples were serially diluted at a starting dilution of 1:500 569 (factoring in absorption volume) in 1% BSA w/vol in PBS and ELISAs were performed as 570 described above. 571
For ELISA data, background antibody binding for each sample at each dilution was subtracted 572 and one-site specific binding curves were fit to the data using GraphPad Prism software. The 573 area under the curve (AUC) was calculated for each curve. For neutralization data, foci in 574 positive control wells which did not receive any serum or antibody were used to adjust for 575 variation between plates. Neutralization data are expressed as the number of foci remaining 576 after absorbing a 1:80 dilution of serum. Assays were performed in triplicate on separate days. 577
For both absorption-neutralization and absorption-ELISA experiments, the RBS mAb 019-10117 578 3C06 mAb and the 041-10047 1C04 mAb (which targets the lower HA head region) were initially 579 diluted to a concentration of 32 μg/mL in 293F media prior to the addition of cells. For 580 absorption-neutralization experiments, the starting concentration for each mAb absorption condition in the FRNT was 16 μg/mL. For absorption-ELISA experiments, the starting 582 concentration for each mAb absorption condition in the ELISA was 3.2 μg/mL. S143P  K144S  N145S  T155Y  H156N  L157P  N158G  F159S  K160T  K189Q  I192T  F193S  D77E  K82E  N121K  R150I  M260I  N285Y  Y98F  S136A S137A  H183A  D190A  L194A  I226N 008-10053 1G05 1.00 1.13 1.00 1.05 1.03 1.00 1.07 0.98 1.02 0.98 1.05 1.03 1.12 0.04 0.92 0.13 0.00 0.97 0.95 
